CR20210306A - Proteínas f de prefusión del vrs estabilizadas - Google Patents

Proteínas f de prefusión del vrs estabilizadas

Info

Publication number
CR20210306A
CR20210306A CR20210306A CR20210306A CR20210306A CR 20210306 A CR20210306 A CR 20210306A CR 20210306 A CR20210306 A CR 20210306A CR 20210306 A CR20210306 A CR 20210306A CR 20210306 A CR20210306 A CR 20210306A
Authority
CR
Costa Rica
Prior art keywords
proteins
fusion rsv
stabilized pre
rsv
stabilized
Prior art date
Application number
CR20210306A
Other languages
English (en)
Inventor
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of CR20210306A publication Critical patent/CR20210306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona proteínas F de prefusión del virus respiratorio sincitial (VRS) estables, composiciones inmunógenas que comprenden dichas proteínas y usos de estas para la prevención y/o el tratamiento de una infección por VRS
CR20210306A 2018-11-13 2019-11-12 Proteínas f de prefusión del vrs estabilizadas CR20210306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205863 2018-11-13
PCT/EP2019/080989 WO2020099383A1 (en) 2018-11-13 2019-11-12 Stabilized pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
CR20210306A true CR20210306A (es) 2021-07-22

Family

ID=64308587

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210306A CR20210306A (es) 2018-11-13 2019-11-12 Proteínas f de prefusión del vrs estabilizadas

Country Status (19)

Country Link
US (1) US20220017574A1 (es)
EP (1) EP3880243A1 (es)
JP (1) JP2022513025A (es)
KR (1) KR20210091749A (es)
CN (1) CN113164583A (es)
AU (1) AU2019377989A1 (es)
BR (1) BR112021008975A2 (es)
CA (1) CA3117275A1 (es)
CL (1) CL2021001212A1 (es)
CO (1) CO2021006308A2 (es)
CR (1) CR20210306A (es)
EA (1) EA202191355A1 (es)
EC (1) ECSP21042554A (es)
IL (1) IL282892A (es)
JO (1) JOP20210106A1 (es)
MX (1) MX2021005607A (es)
PE (1) PE20211469A1 (es)
SG (1) SG11202104522UA (es)
WO (1) WO2020099383A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
JP2024509756A (ja) * 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
WO2023055154A1 (ko) * 2021-09-29 2023-04-06 에스케이바이오사이언스 주식회사 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EA021393B1 (ru) 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
JP5796011B2 (ja) 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
KR101778317B1 (ko) * 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
MX2015013065A (es) * 2013-03-13 2016-06-06 Us Health Proteinas f de rsv de prefusion y su uso.
CN105189756B (zh) * 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2016040556A1 (en) * 2014-09-12 2016-03-17 Rsv Corporation Virosomes containing respiratory syncytial virus strain line 19 fusion protein and uses thereof
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6840718B2 (ja) * 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
BR112018008708A2 (pt) * 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
BR112018010805A2 (pt) * 2015-12-23 2018-11-27 Pfizer Inc. mutantes de proteína f de rsv
US11174292B2 (en) * 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
IL264119B2 (en) * 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion

Also Published As

Publication number Publication date
JP2022513025A (ja) 2022-02-07
ECSP21042554A (es) 2021-11-30
CL2021001212A1 (es) 2021-10-22
JOP20210106A1 (ar) 2023-01-30
PE20211469A1 (es) 2021-08-05
EA202191355A1 (ru) 2021-09-20
KR20210091749A (ko) 2021-07-22
EP3880243A1 (en) 2021-09-22
WO2020099383A1 (en) 2020-05-22
CN113164583A (zh) 2021-07-23
MX2021005607A (es) 2021-06-30
SG11202104522UA (en) 2021-05-28
IL282892A (en) 2021-06-30
BR112021008975A2 (pt) 2021-08-17
AU2019377989A1 (en) 2023-10-05
US20220017574A1 (en) 2022-01-20
CO2021006308A2 (es) 2021-05-31
CA3117275A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
CR20210306A (es) Proteínas f de prefusión del vrs estabilizadas
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
MY201791A (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
PH12015502735B1 (en) Stabilized soluble pre-fusion rsv f polypeptides
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
EA201070794A1 (ru) Рекомбинантные антигены rsv
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2021013111A (es) Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MX2023009738A (es) Antigenos de rsv fb prefusion estabilizados.
TR201905336T4 (tr) Rekombinant rsv antijenleri.